need to identify novel effective biomarkers and to develop new therapeutic strategies.
Y-box binding protein-1 (YBX1), encoded by the YBX1 gene, is a member of the cold-shock protein superfamily and participates in a wide variety of cellular processes. 7 Many studies have indicated that YBX1 expression is significantly elevated and correlates with poor outcome and recurrence in common tumor types, such as pancreatic cancer and melanoma. 8, 9 In addition, YBX1 regulates tumor cell proliferation, apoptosis, invasion, migration and chemoresistance through the related pathways. 10 Multiple key molecules that interact with YBX1
have been shown to be overexpressed in chordoma and contribute to chordoma development, such as hypoxia inducible factor 1 alpha subunit (HIF-1α), a mechanistic target of rapamycin kinase (mTOR) and RB transcriptional corepressor 1 (RB). 6, [11] [12] [13] [14] Receptor tyrosine kinases (RTK) have been proved to participate in the tumorigenesis and development of chordoma. The epidermal growth factor receptor (EGFR) is the most significantly activated RTK in chordoma. 15 Studies have indicated that EGFR inhibitors significantly reduce the tumor growth and invasion ability of chordoma in vitro and vivo. 16, 17 Numerous studies have shown that YBX1 enhances EGFR expression and activates EGFR-mediated pathways, promoting the aggressive malignant phenotypes in multiple tumors. 18, 19 However, to our knowledge, the functional role and regulatory mechanism of YBX1 in chordoma have not been investigated. Based on the theoretical evidence mentioned above, we hypothesized that YBX1 is involved in the tumorigenesis and progression of chordoma through EGFR-mediated pathways.
In this study, we examined the expression, biological functions and molecular mechanisms of YBX1 in chordoma. Our results showed that YBX1 promoted tumorigenesis and the progression of chordoma via the EGFR/AKT pathway, suggesting that YBX1 could be a prognostic biomarker and a promising therapeutic target for chordoma.
| MATERIAL S AND ME THODS

| Patients and tumor tissues
All cases of spinal chordoma diagnosed at Peking University Third
Hospital between 2008 and 2016 were considered for enrolment.
A total of 32 patients (20 men and 12 women) who had no preoperative treatment were included in the study, with an average age of 50.3 years (range, 11-70 years). All patients underwent surgery at our department. Nineteen distant normal tissues obtained at least 3 cm from the surgical margins were collected as controls. The average follow-up period was 52.9 months (range, 5-121 months). We retrospectively reviewed clinicopathological characteristics, including age, sex, tumor location, tumor size, surrounding muscle invasion, recurrence, length of follow-up and disease status. The present study was conducted with the approval of the Ethics Committee of the Peking University Third Hospital Institutional Review Board (No.
IRB00006761-2016048). Written informed consent was obtained
from all patients whose specimens and clinical information were used for this study. The percentage of positive cells was graded as follows: 0 (none); 1 (<25%); 2 (26%-50%); 3 (50%-75%); and 4 (>75%). The intensity of immunoreactivity was graded as follows: 0 (no reaction); 1 (weak); 2 (moderate); and 3 (strong). The final score was the product of these 2 indices and ranged from 0 to 12. As the mean IRS was 7.6, samples with IRS ≤6
| Immunohistochemistry
and IRS ≥8 were classified as low and high YBX1 expression, respectively.
Immunohistochemical staining of phospho-EGFR and phosphoAkt expression in tissue samples were also performed using primary 
| Chordoma cell lines and cell culture
Human chordoma cell lines U-CH1 (CRL-3217) and MUG-Chor1
(CRL-3219) were purchased from American Type Culture Collection (Manassas, VA, USA) and were cultivated in Iscove's modified Dulbecco's medium (IMDM) and RPMI medium (HyClone, Logan, UT, USA) at a ratio of 4:1 supplemented with 10% FBS (Gibco, Grand
Island, NY, USA), 2 mmol/L L-glutamine (HyClone), 100 U/mL penicillin and 100 μg/mL streptomycin (PS, HyClone) at 37°C in a humidified atmosphere of 95% air and 5% CO 2 . Culture flasks were coated with rat tail type I collagen (Corning, Bedford, MA, USA) prior to use.
| Lentivirus packaging and infection
To knockdown the endogenous YBX1 gene, shRNA targeting YBX1 was synthesized and cloned into the pLL3.7-U6-EGFP lentivirus vector (Addgene, Watertown, MA, USA). A scrambled plasmid was used as a negative control.
For YBX1 gene overexpression, the full length CDS of the YBX1 gene was cloned into the pHIV-EGFP-lentivirus vector and an empty plasmid was used as a control. The knockdown and overexpression effects of YBX1 were detected by western blot (WB).
The lentivirus overexpressing YBX1 and the control lentivirus were termed YBX1 HA and Ctrl HA, respectively. The lentiviruses expressing YBX1 shRNA1, YBX1 shRNA2 and the control lentivirus were termed YBX1 shRNA1, YBX1 shRNA2 and shRNA Ctrl, respectively.
| Nucleus pulposus cell isolation and culture
Human intervertebral disc nucleus pulposus tissues were collected from patients with lumbar disc herniation or lumbar spinal stenosis.
The tissues were rinsed 3 times with sterile PBS with 1% penicillinstreptomycin to remove any residual blood and minced into small 
| Western blot analysis
| Transwell invasion assay
Cell invasion assays were performed in Boyden chambers contain- and counted using light microscopy. 
| Annexin V-FITC/PI apoptosis assay
| Cell cycle analysis
For cell cycle analysis, the collected cells were fixed in ice-cold 70%
ethanol for 1 hour and re-suspended in PBS with .1% BSA. Then, the fixed cells were stained with PI (20 μg/mL) containing RNase (1 μg/ mL) for 20 min in the dark. The cells were run on a FACSCalibur flow cytometer (Cytoflex; Beckman Coulter, USA). The data were analyzed using CELL Quest software (BD Biosciences). Table 1 .
| ChIP
| Dual luciferase reporter assays
U-CH1 and MUG-Chor1 cells were co-transfected with firefly luciferase reporter plasmid containing the EGFR promoter (GeneChem, Shanghai, China) and an expression plasmid encoding HA-YBX1, together with pRL-TK (Renilla) control plasmid, using Lipofectamine 2000 (Invitrogen). Luciferase activity was measured using the DualLuciferase Reporter Kit (Promega). For data analysis, the luciferase activity was measured relative to Renilla to standardize the background signal. Animal experiments were performed in accordance with the policies and principles of laboratory animal care of the Peking University of Medicine Animal Care and Use Committee.
| Subcutaneous xenograft model
| Immunofluorescence microscopy
For immunofluorescence analysis, monolayers of cells were grown on a confocal dish (NEST, Guangzhou, China). The cells were fixed in 4% paraformaldehyde for 15 minutes and permeabilized with PBS containing .5% TritonX-100. Blocking was performed with 5%
BSA, and the cells were subsequently incubated overnight at 4°C
with primary antibody (1:100, ab76149, abcam). FITC-conjugated rabbit anti-goat IgG (1:500, ab150079, abcam) was used as the secondary antibody. The cell nuclei were counterstained with 10 μg/ mL 4′,6-Diamidino-2-phenylindole (DAPI) solution (C0065, Solarbio, Beijing, China). Images were obtained and analyzed using a confocal microscope (TCS-SP8, Leica, Wetzlar, Germany).
| Statistical analysis
All statistical analyses were performed using SPSS software 22.0 (IBM, Armonk, NY, USA). Continuous data were presented as mean ± SD. A 2-tailed unpaired Student's test was used to assess the statistical significance of independent data. For multiple comparisons, a one-way ANOVA analysis was used. The associations between YBX1 expression and clinicopathological characteristics were evaluated using the Fisher exact probability test. Kaplan-Meier statistics, log-rank tests and the Cox proportional hazards regression model were used to examine the relationship between YBX1 expression and patients' survival rate. A P-value of <.05 based on 2-tailed tests was considered significant.
| RE SULTS
| YBX1 is overexpressed in spinal chordoma tissues and cells
Immunohistochemical results demonstrated that YBX1 was ( Figure 1C-F, S1 ). YBX1 was localized in both nucleus and cytoplasm in U-CH1 cell line examined by immunofluorescence microscopy ( Figure S2 ). In addition, immunohistochemical staining showed that tumor cells exhibited positive staining for p-EGFR and p-Akt. YBX1 expression was correlated to p-EGFR and p-Akt expression in chordoma ( Figure S2 , Table S2 ). Our results showed that YBX1 and p-YBX1 expression was significantly upregulated in chordoma tissues and cells.
| YBX1 overexpression is associated with surrounding tissue invasion, recurrence and poor prognosis
Based on the immunohistochemical analysis, the samples were classified into 2 staining groups: low expression (YBX1 score ≤6, n = 12) and high expression (YBX1 score ≥8, n = 20) group. Fisher exact probability test analysis indicated that high YBX1 expression was not significantly analysis of YBX1 expression in tissues and cell lines. **P < .01. NC, normal control tissues group; NP, nucleus pulposus cell group; T, tumor group. E, F, Western blot analysis of YBX1 and p-YBX1 expression in tissues and cell lines. G, Kaplan-Meier survival analysis of overall survival rate and continuous disease-free survival rate associated with patient age (P = .726), sex (P = 1.000), tumor location (P = .726) or tumor size (P = .647). In samples from patients that pre- proportional hazard models were performed. High YBX1 expression was significantly associated with poor overall survival (OS) and continuous disease-free survival (CDFS) (log-lank test, P = .03 for OS, P = .017 for CDFS; Figure 1G , Table S3 ). Multivariate Cox regression analysis revealed that YBX1 expression was an independent prognostic marker for OS in patients with chordoma (P = .034, HR = 6.796, 95% CI 1.157-39.934; Table S4 ).
| YBX1 promotes chordoma cell proliferation
To investigate the functional role of YBX1 in cellular proliferation in chordoma, we constructed YBX1 overexpression and knockdown systems by transfecting both cell lines with pHIV-EGFP-YBX1 and pLL3.7-U6-shRNA-YBX1. The overexpression and downregulated expression of YBX1 and p-YBX1 were confirmed by western blot in both U-CH1
and MUG-Chor1 cells (Figure 2A ).
After culturing with pLL3.7-U6-shRNA-YBX1 for 4 and 7 days, cell viability was inhibited in both U-CH1 and MUG-Chor1 cell lines. The proliferation of U-CH1 and MUG-Chor1 cells harboring YBX1 shRNA1
and YBX1 shRNA2 was remarkably decreased at 4 days and 7 days. The proliferation of U-CH1 and MUG-Chor1 cells harboring YBX1-HA was remarkably increased at 4 and 7 days ( Figure 2B ).
The results of the colony formation assay also showed that YBX1 promoted cell proliferation in chordoma. The number of colonies formed in the 2 YBX1-knockdown groups was lower than that in the corresponding control group. The number of colonies was significantly higher in the YBX1-overexpression groups than in the corresponding control groups ( Figure 2C,D) .
| YBX1 enhances chordoma cell invasion
The results of transwell invasion chamber assays showed that the in- 
| YBX1 knockdown induces apoptosis of chordoma cells
The apoptosis rate in the control group was higher compared with that in the YBX1-overexpression group of U-CH1 cells and MUG-Chor1
( Figure 4A,B) . The apoptosis rate in the control group was lower compared with that in the YBX1-knockdown group of U-CH1 and MUGChor1 cells ( Figure 4C,D) . There was an increase in the proportion of cells in S phase and a decrease in the proportion of cells in G0/G1 phases in the YBX1-overexpression groups compared with that in the Ctrl-HA groups in both cell lines. These data suggest that YBX1 overexpression accelerates the G1/S transition.
| YBX1 knockdown induces cycle arrest in chordoma cells
TA B L E 3 Association of YBX1 expression with clinical characteristics in chordomas
Characteristics Number 
YBX1 expression
P-value
| YBX1 binds to the enhanced epidermal growth factor receptor promoter to enhance transcription in chordoma cells
Enhanced epidermal growth factor receptor is frequently the most significantly activated RTK in chordomas. Based on the observation that YBX1 binds to the EGFR promoter in breast cancer, we investigated whether YBX1 positively regulates EGFR promoter activity in chordoma. We determined that YBX1 was able to stimulate EGFR promoter activity using a luciferase reporter construct. EGFR luciferase promoter activity in cells co-transfected with the YBX1 expression vector was significantly higher than that with empty vector. The promoter activity correlates positively with the concentration of YBX1 expression vector in both U-CH1 and MUG-Chor1 cells ( Figure S3 ). showing YBX1-promoted cell proliferation, n = 3, mean ± SD. *P < .05, **P < .01, ***P < .001. C, D, Representative images and numbers of colony formation assay showing YBX1-promoted cell proliferation, n = 3, mean ± SD. **P < .01, ***P < .001
Next, we performed ChIP assays to determine whether YBX1 directly binds the EGFR promoter in chordoma cells. The YBX1 antibody effectively immunoprecipitated the DNA amplified by the EGFR primer compared with the immunoglobulin (IgG) controls ( Figure S3 ). These results suggest that YBX1 regulates EGFR transcription by binding to the region of its promoter.
| YBX1 is involved in the EGFR/AKT pathway in chordoma
As YBX1 transactives EGFR in chordoma, we furthermore confirmed that YBX1 could activate the EGFR pathway in chordoma. We examined EGFR, p-EGFR expression in chordoma cells with YBX1 overexpression.
Western blot results showed that YBX1 overexpression increased p-EGFR 
| YBX1 promotes chordoma tumor growth in vivo
To evaluate the effects of YBX1 on chordoma growth in vivo, we established a The results of statistical analysis of total apoptosis rate, n = 3, mean ± SD. **P < .01. C, D, YBX1 knockdown: Pictures of cell apoptosis detected by flow cytometry and the results of statistical analysis of total apoptosis rate, n = 3, mean ± SD. *P < .05, **P < .01, ***P < .001
Similarly, cell cycle analysis showed that there was delayed G1/S transition with YBX1 knockdown and accelerated G1/S transition with YBX1 overexpression in chordoma. In sum, YBX1 promoted cell growth and regulated cell cycle progression at G1/S in chordoma.
Apoptosis is programmed cell death, a vital haemostasis mechanism that maintains the cell population in tissues and prevents cancer development. The Bcl-2 family of proteins regulate mitochondrial membrane permeability and have special significance in the process of apoptosis. Bcl-2 is the representative of anti-apoptotic proteins and
Bax belongs to the pro-apoptotic proteins. Tumor suppressor protein P53 regulates the repair of cellular DNA and its abnormal state correlates to apoptosis in cell process. 28 Cleaved caspase 3 and cleaved PARP1 are common apoptosis markers. Lasham observed that YBX1
is a negative regulator of P53, protecting cells from P53-mediated apoptosis. 29 Manik reports that YBX1 knockdown induces apoptosis in multiple myeloma cells. 30 In addition, Wang found that YBX1 overexpression also increased Bax, decreased Bcl-2 expression, and induced apoptosis in vascular endothelial cells. 31 In accordance with the previous studies above, our study showed that YBX1 was a negative regulator of apoptosis in chordoma.
Receptor tyrosine kinases are the key regulators of cellular processes and play an important role in tumor development and progression. As in breast cancer and glioma. 18, 19 In our study, immunohistochemical staining showed that YBX1 expression was correlated to p-EGFR and p-Akt expression in chordoma. These data supported the hypothesis that YBX1 was involved in chordoma development through the EGFR pathway. We observed that YBX1 promoted the transcriptional activation of EGFR promoter via a luciferase reporter system using chordoma cells. Furthermore, we performed ChIP assays that clearly revealed that YBX1 directly regulated EGFR transcription by binding to its promoter in chordoma cell lines. Indeed, we observed that YBX1 overexpression promoted the expression of p-EGFR in chordoma cell lines.
As the major downstream pathway of EGFR, the AKTmediated pathway plays a critical role in tumorigenesis. Bin reports that YBX1 promotes epithelial-mesenchymal transition via AKT activation in lung adenocarcinoma cells. 32 Sinnberg suggests that YBX1 activation contributes to the increased activity of the PI3K/AKT pathway in melanoma cells. 33 Consistent with previous studies, we found that YBX1 activated the AKT pathway in chordoma. In summary, our results suggest that YBX1 acts as an oncogene, promoting tumorigenesis and progression via the EGFR/AKT pathway in spinal chordoma. Accordingly, we believe that YBX1 may serve as a clinically useful biomarker and a promising molecular target for chordoma.
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